163 related articles for article (PubMed ID: 23894399)
1. FAS/FASL expression profile as a prognostic marker in squamous cell carcinoma of the oral cavity.
de Carvalho-Neto PB; dos Santos M; de Carvalho MB; Mercante AM; dos Santos VP; Severino P; Tajara EH; Louro ID; da Silva-Conforti AM
PLoS One; 2013; 8(7):e69024. PubMed ID: 23894399
[TBL] [Abstract][Full Text] [Related]
2. FAS ligand expression in inflammatory infiltrate lymphoid cells as a prognostic marker in oral squamous cell carcinoma.
Peterle GT; Santos M; Mendes SO; Carvalho-Neto PB; Maia LL; Stur E; Agostini LP; Silva CV; Trivilin LO; Nunes FD; Carvalho MB; Tajara EH; Louro ID; Silva-Conforti AM
Genet Mol Res; 2015 Sep; 14(3):11145-53. PubMed ID: 26400345
[TBL] [Abstract][Full Text] [Related]
3. A Fas Ligand (FasL)-Fused Humanized Antibody Against Tumor-Associated Glycoprotein 72 Selectively Exhibits the Cytotoxic Effect Against Oral Cancer Cells with a Low FasL/Fas Ratio.
Chien MH; Chang WM; Lee WJ; Chang YC; Lai TC; Chan DV; Sharma R; Lin YF; Hsiao M
Mol Cancer Ther; 2017 Jun; 16(6):1102-1113. PubMed ID: 28292939
[TBL] [Abstract][Full Text] [Related]
4. Fas receptor (CD95) & Fas ligand (CD178) expression in patients with tobacco-related intraoral squamous cell carcinoma.
Das SN; Khare P; Singh MK; Sharma SC
Indian J Med Res; 2011 Jul; 134(1):54-60. PubMed ID: 21808135
[TBL] [Abstract][Full Text] [Related]
5. Effects of FasL expression in oral squamous cell cancer.
Fang L; Sun L; Hu FF; Chen QE
Asian Pac J Cancer Prev; 2013; 14(1):281-5. PubMed ID: 23534738
[TBL] [Abstract][Full Text] [Related]
6. Expression of ADAM10, Fas, FasL and Soluble FasL in Patients with Oral Squamous Cell Carcinoma (OSCC) and their Association with Clinical-Pathological Parameters.
Zepeda-Nuño JS; Guerrero-Velázquez C; Del Toro-Arreola S; Vega-Magaña N; Ángeles-Sánchez J; Haramati J; Pereira-Suárez AL; Bueno-Topete MR
Pathol Oncol Res; 2017 Apr; 23(2):345-353. PubMed ID: 27628319
[TBL] [Abstract][Full Text] [Related]
7. Expression of fas (CD95) ligand is correlated with IL-10 and granulocyte colony-stimulating factor expression in oral and oropharyngeal squamous cell carcinoma.
Fujieda S; Sunaga H; Tsuzuki H; Fan GK; Ito T; Sugimoto C; Saito H
Cancer Lett; 2000 Dec; 161(1):73-81. PubMed ID: 11078915
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer.
Shibakita M; Tachibana M; Dhar DK; Kotoh T; Kinugasa S; Kubota H; Masunaga R; Nagasue N
Clin Cancer Res; 1999 Sep; 5(9):2464-9. PubMed ID: 10499620
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility to oral cancers with CD95 and CD95L promoter SNPs may vary with the site and gender.
Daripally S; Nallapalle SR; Katta S; Prasad VV
Tumour Biol; 2015 Sep; 36(10):7817-30. PubMed ID: 25944167
[TBL] [Abstract][Full Text] [Related]
10. Expression of Fas/FasL in patients with oral lichen planus.
Hadzi-Mihailovic M; Raybaud H; Monteil R; Jankovic L
J BUON; 2009; 14(3):487-93. PubMed ID: 19810143
[TBL] [Abstract][Full Text] [Related]
11. Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer.
Reimer T; Koczan D; Müller H; Friese K; Thiesen HJ; Gerber B
Breast Cancer Res; 2002; 4(5):R9. PubMed ID: 12223126
[TBL] [Abstract][Full Text] [Related]
12. Low expression of CD40L in tumor-free lymph node of oral cavity cancer related with poor prognosis.
Rah YC; Ahn JC; Jeon EH; Kim H; Paik JH; Jeong WJ; Kwon SY; Ahn SH
Int J Clin Oncol; 2018 Oct; 23(5):851-859. PubMed ID: 29761306
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of Fas ligand and down-regulation of Fas expression in oral carcinogenesis.
Chen Q; Samaranayake LP; Zhen X; Luo G; Nie M; Li B
Oral Oncol; 1999 Nov; 35(6):548-53. PubMed ID: 10705088
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma.
Lerma E; Romero M; Gallardo A; Pons C; Muñoz J; Fuentes J; Lloveras B; Catasus L; Prat J
Virchows Arch; 2008 Jan; 452(1):65-74. PubMed ID: 18000680
[TBL] [Abstract][Full Text] [Related]
15. Suppression of Fas receptor and negative correlation of Fas ligand with differentiation and apoptosis in oral squamous cell carcinoma.
Loro LL; Vintermyr OK; Johannessen AC; Liavaag PG; Jonsson R
J Oral Pathol Med; 1999 Feb; 28(2):82-7. PubMed ID: 9950255
[TBL] [Abstract][Full Text] [Related]
16. Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy.
Botti C; Buglioni S; Benevolo M; Giannarelli D; Papaldo P; Cognetti F; Vici P; Di Filippo F; Del Nonno F; Venanzi FM; Natali PG; Mottolese M
Clin Cancer Res; 2004 Feb; 10(4):1360-5. PubMed ID: 14977837
[TBL] [Abstract][Full Text] [Related]
17. Tumor Budding, EMT and Cancer Stem Cells in T1-2/N0 Oral Squamous Cell Carcinomas.
Attramadal CG; Kumar S; Boysen ME; Dhakal HP; Nesland JM; Bryne M
Anticancer Res; 2015 Nov; 35(11):6111-20. PubMed ID: 26504037
[TBL] [Abstract][Full Text] [Related]
18. [Expression of Fas, Fas ligand, Fas-associated death domain protein, caspase 8 and mutant P53 protein in esophageal squamous cell carcinoma].
Xue LY; Ren LQ; Luo W; Guan XJ; Zou SM; Zheng S; Bi R; Xie YQ; He ZG; Lü N
Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(3):150-4. PubMed ID: 17425843
[TBL] [Abstract][Full Text] [Related]
19.
Costa EFD; Lima TRP; Lopes-Aguiar L; Nogueira GAS; Visacri MB; Quintanilha JCF; Pincinato EC; Calonga L; Mariano FV; Altemani AMAM; Altemani JMC; Moriel P; Chone CT; Ramos CD; Lima CSP
Tumour Biol; 2020 Jul; 42(7):1010428320938494. PubMed ID: 32628088
[TBL] [Abstract][Full Text] [Related]
20. High HMGA2 Expression Correlates with Reduced Recurrence-free Survival and Poor Overall Survival in Oral Squamous Cell Carcinoma.
Fang CY; Liew PL; Chen CL; Lin YH; Fang CL; Chen WY
Anticancer Res; 2017 Apr; 37(4):1891-1899. PubMed ID: 28373457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
